Eligibility Details:
Inclusion Criteria:
1. Diagnosis and treatment for heart failure (HF) (regardless of left ventricular
ejection fraction (LVEF)) for > 90 days prior to the date of consent:
a. Subjects should be on stable, optimally titrated medical therapy for at least 30
days, as recommended according to current American Heart Association (AHA)/American
College of Cardiology (ACC) guidelines as standard-of-care for HF therapy in the
United States, with any intolerance documented.
2. GUIDE-HF Randomized Arm Only: NYHA Class II, III or IV HF symptoms documented within
30 days prior to consent.
3. GUIDE-HF Single Arm Only: NYHA Class III HF symptoms documented within 30 days prior
to consent.
4. HF hospitalization (HFH) within 12 months prior to consent and/or elevated N-terminal
pro-Brain Natriuretic Peptide (NT-proBNP) (or Brain Natriuretic Peptide (BNP)) within
30 days prior to consent defined as:
1. Subjects with LVEF ≤ 40%: NT-proBNP ≥ 1000 pg/mL (or BNP ≥ 250 pg/mL).
2. Subjects with LVEF > 40%: NT-proBNP ≥ 700 pg/mL (or BNP ≥ 175 pg/mL).
3. Thresholds for NT-proBNP and BNP (for both LVEF ≤ 40% and LVEF > 40%) will be
corrected for body mass index (BMI) using a 4% reduction per BMI unit over 25
kg/m2
5. ≥ 18 years of age
6. Chest circumference of < 65 inches, if BMI is > 35 kg/m2
7. Written informed consent obtained from subject
8. Willing and able to upload pulmonary artery (PA) pressure information and comply with
the follow-up requirements
Exclusion Criteria:
1. Intolerance to all neuro-hormonal antagonists (i.e., intolerance to angiotensin
converting enzyme-inhibitors (ACE-I), angiotensin receptor blockers (ARB),
angiotensin-neprilysin inhibitors (ARNi), hydralazine/isosorbide dinitrate and
beta-blockers)
2. ACC/AHA Stage D refractory HF (including having received or currently receiving
pharmacologic circulatory support with inotropes)
3. Received or are likely to receive an advanced therapy (e.g., mechanical circulatory
support or cardiac transplant) in the next 12 months
4. NYHA Class IV HF patients with:
1. Continuous or chronic use of scheduled intermittent inotropic therapy for HF and
an INTERMACS level of ≤ 4, OR
2. Persistence of fluid overload with maximum (or dose equivalent) diuretic
intervention
5. Glomerular Filtration Rate (eGFR) < 25 mL/min and non-responsive to diuretic therapy,
or receiving chronic dialysis
6. Inability to tolerate or receive dual antiplatelet therapy or anticoagulation therapy
for one month post-implantation
7. Significant congenital heart disease that has not been repaired and would prevent
implantation of the CardioMEMSâ„¢ PA Sensor
8. Implanted with mechanical right heart valve(s)
9. Unrepaired severe valvular disease
10. Pregnant or planning to become pregnant in the next 12 months
11. An active, ongoing infection, defined as being febrile, an elevated white blood cell
count, on intravenous antibiotics, and/or positive cultures (blood, sputum or urine).
12. History of current or recurrent (≥ 2 episodes within 5 years prior to consent)
pulmonary emboli and/or deep vein thrombosis
13. Major cardiovascular event (e.g., unstable angina, myocardial infarction, percutaneous
coronary intervention, open heart surgery, or stroke, etc.) within 90 days prior to
consent
14. Implanted with Cardiac Resynchronization Therapy (CRT)-Pacemaker (CRT-P) or
CRT-Defibrillator (CRT-D) for less than 90 days prior to consent
15. Enrollment into another trial with an active treatment arm
16. Anticipated life expectancy of < 12 months
17. Any condition that, in the opinion of the Investigator, would not allow for
utilization of the CardioMEMSâ„¢ HF System to manage the subject using information
gained from hemodynamic measurements to adjust medications, including the presence of
unexpectedly severe pulmonary hypertension (e.g., trans-pulmonary gradient >15) at
implant right heart catheterization (RHC), a history of non-compliance, or any
condition that would preclude CardioMEMSâ„¢ PA Sensor implantation
common.study.methods.has-drugs-no
common.study.methods.is-healthy-yes
